Home ▶ Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS ▶ Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS View Full Press Release Travere Therapeutics to Participate at Upcoming Investor Conferences Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results